资讯

Clinical Trials Arena5 小时
MSD and Daiichi announce first subject dosing in prostate cancer trial
MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...
Medical Dialogues6 小时
Phase 3 trial initiated for Ifinatamab Deruxtecan in Pretreated Metastatic Castration ...
Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...